Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

MorphoSys AG. (8/1/18). "Press Release: MorphoSys AG Reports Second Quarter 2018 Financial Results". Planegg.

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
Products Product tafasitamab (MOR208 / XmAb5574)
  Product 2 Tremfya™
Index term Index term MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market
Persons Person Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)
  Person 2 Herron, Jennifer (ADC Therapeutics 201911– CCO based in US before Immunogen + MorphoSys US + Ariad + BMS)
     


   
Record changed: 2018-08-11

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top